Cytek Biosciences (CTKB) Long-Term Deferred Tax (2020 - 2025)

Cytek Biosciences' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $38.4 million for Q3 2025.

• Quarterly Long-Term Deferred Tax rose 24.74% year-over-year to $38.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $38.4 million (up 24.74% YoY) and the FY2024 annual result came in at $33.4 million, up 9.47% from the prior year.
• Long-Term Deferred Tax was $38.4 million for Q3 2025 at Cytek Biosciences, up from $35.8 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $38.4 million in Q3 2025 and bottomed at $7.4 million in Q2 2021.
• A 5-year average of $23.3 million and a median of $25.2 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax surged 125.74% — and 2025, when it advanced 3.06%.
• Cytek Biosciences' Long-Term Deferred Tax stood at $9.2 million in 2021, then soared by 123.03% to $20.5 million in 2022, then surged by 49.02% to $30.5 million in 2023, then advanced by 9.47% to $33.4 million in 2024, then gained by 15.04% to $38.4 million in 2025.
• Business Quant data shows CTKB's Long-Term Deferred Tax at $38.4 million in Q3 2025, $35.8 million in Q2 2025, and $33.7 million in Q1 2025.